Videos

Mark Fleming, MD, and Manoj Bupathi, MD, MS, highlight the key studies and sessions in GU oncology that they're most anticipating at ASCO 2026.

Objective performance indicators in robotic surgery are providing the first quantitative framework for evaluating surgical technique, according to Michael Stifelman, MD, professor and chair of urology at Hackensack Meridian Health, whose early prostatectomy data link specific intraoperative metrics to functional outcomes—while governance frameworks, cultural adoption, and the prospect of real-time intraoperative guidance define the near-term challenges and long-term trajectory.

Break Wave lithotripsy met all pivotal non-inferiority end points vs shock wave lithotripsy.

Bilal I. Chughtai, MD, highlights 12-month cystoscopic data from the pivotal IDE trial of the Zenflow Spring System.

In this episode, “The Emerging Perioperative Era in MIBC with the NIAGARA Trial,” the expert faculty explore how the NIAGARA trial is reshaping the treatment landscape for muscle-invasive bladder cancer (MIBC). The panel reviews the clinical data supporting perioperative durvalumab plus gemcitabine-cisplatin (GC) in cisplatin-eligible patients, including findings related to pathologic complete response, event-free survival, overall survival, and safety, and discusses how these outcomes are influencing treatment strategies in clinical practice.

Welcome back to another Urology Times Peer Exchange series. In this episode titled, “The Evolving Treatment Landscape in MIBC,” the expert faculty discuss how the treatment landscape for muscle-invasive bladder cancer (MIBC) is evolving with the emergence of perioperative treatment strategies that integrate systemic therapy before and after surgery.

Keith Xavier, MD, URPS, highlights data from the TITAN 2 study looking at the impact of site of service on outcomes with the Medtronic implantable tibial neuromodulation system.

In this video, R. Jeffrey Karnes, MD, describes the design of the Mayo Clinic external validation study of the post-RP MMAI model, including the rationale for focusing on a long-term survivor cohort, the structure of the MMAI score, and the primary and secondary end points used in the analysis.

Archan Khandekar, MD, highlights key findings from a study evaluating LLM architectures for answering patient-facing urologic questions.

In this video, C. Shawn West, MD, outlines future trends in BPH management, including reimbursement considerations, evolving technologies, and the growing role of early intervention.

In this video, Neal D. Shore, MD, FACS, and Rana R. McKay, MD, FASCO, discuss the evolving treatment landscape for metastatic hormone-sensitive prostate cancer and the clinical rationale for evaluating darolutamide (Nubeqa) plus ADT in a US patient population.

Mark D. Tyson II, MD, MPH, discusses findings from the phse 3b PATAPSCO study, evaluating durvalumab plus BCG for patients with BCG-naïve, high-risk NMIBC.

Mark Garzotto, MD, discusses phase 3 data on aglatimagene besadenovec plus standard-of-care external beam radiation therapy with or without short-course androgen deprivation therapy in localized prostate cancer.

Bashir Al Hussein Al Awamlh, MD, MPH, discusses findings from an international registry study evaluating how baseline sexual interest may influence sexual bother outcomes after treatment for localized prostate cancer.

Sarah P. Psutka, MD, MSc, reflects on her AUA 2026 talk regarding frailty and surgical outcomes in urologic oncology.

R. Jeffrey Karnes, MD, frames the ongoing challenge of post–radical prostatectomy prognostication and explains the key criteria urologists should apply when evaluating new AI-based prognostic tools, including the centrality of external validation and patient population diversity.

Rana R. McKay, MD, FASCO, shares results from the ARASEC study, which evaluated darolutamide plus ADT in mHSPC using a novel external control-arm design.

In this video, recorded at the 2026 American Urological Association Annual Meeting in Washington, DC, Murilo De Almeida Luz, MD, gives an overview of the DAROL study design and key findings.

In this segment, C. Shawn West, MD, discusses patient selection, procedural technique, and optimization strategies for the prostatic urethral lift (UroLift).

The phase 1/2 ResQ133A-NMIBC trial (NCT06800963) is evaluating intravesical recombinant BCG in patients with BCG-naïve high-risk NMIBC across US sites, with safety as the primary end point and complete response and disease-free survival as secondary end points, building on European data showing 50% response rates and no dose-limiting toxicities in BCG-unresponsive disease.

Michael S. Cookson, MD, MMHC, FACS, unpacks the significance of the phase 2 ARASEC trial evaluating darolutamide in mHSPC.

The 2025 AUA Census documents significant geographic maldistribution of the urologic workforce—with 62% of US counties lacking a urologist—alongside a median practitioner age of 54 and generational shifts in career expectations that together pose near-term workforce sustainability challenges.

The INTIBIA Pivotal Study—the first sham-controlled, double-blind RCT of an implantable tibial nerve stimulation device—demonstrated significantly greater clinically meaningful improvements in symptom bother, health-related quality of life, and patient global impression at 3 months compared with sham, with durable benefits through 12 months.

Chad A. Reichard, MD, highlights real-world data presented at AUA 2026 on re-induction with nadofaragene firadenovec in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

ARASEC provides US-based, contemporary evidence supporting darolutamide plus ADT in metastatic hormone-sensitive prostate cancer, demonstrating a 71% reduction in prostate cancer-specific mortality compared with a historical ADT control—while its use of propensity score matching with an external phase 3 control arm represents a novel trial design that may inform future studies in rapidly evolving treatment landscapes.

In this interview, Kari A.O. Tikkinen, MD, PhD, explains why effective nocturia management in geriatric patients requires systematic phenotyping across 4 primary subtypes—nocturnal polyuria, reduced bladder capacity, bladder outlet obstruction, and sleep-driven causes—rather than empiric pharmacologic treatment, with many cases requiring interdisciplinary referral rather than urologic intervention alone.

Health services research at UNC is informing community-based outreach efforts in prostate cancer—including engagement with HBCUs and patient groups across North Carolina—by centering patient and community perspectives to identify and address the barriers that prevent evidence-based care from reaching those who need it most.

Adam B. Weiner, MD, is joined by Mary Beth Westerman, MD, FACS, to discuss the landmark CISTO trial—a large pragmatic study examining patient-reported outcomes among individuals with high-risk non–muscle invasive bladder cancer who underwent either bladder-sparing therapy or radical cystectomy.

A real-world analysis found that PSADT was undocumented in most patients with high-risk biochemical recurrence of prostate cancer, potentially delaying treatment initiation and underestimating progression risk.

Krishnan discusses how prolapse stage, patient lifestyle, and nuanced mesh counseling inform individualized decision-making around robotic sacrocolpopexy vs vaginal reconstructive repair.